CoChat

CSF p-tau increase in response to Aβ-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles

Open access
Kaeser, Stephan A., Häsler, Lisa M., Lambert, Marius, Bergmann, Carina, Bottelbergs, Astrid, Theunis, Clara, Mercken, Marc, Jucker, Mathias · 2022 · Acta Neuropathologica
Cited by 41

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Phosphorylated tau (p-tau) species in bodily fluids are among the most reliable molecular biomarkers for differential diagnosis and progression monitoring of Alzheimer’s disease (AD) [3]. The ATN research framework stages AD patients based on three classes of readouts, amyloid (A), tau (T) and neurodegeneration (N) including cerebrospinal fluid (CSF) and imaging biomarkers [6]. CSF p-tau together with positron emission tomography (PET) for tau are suggested biomarkers of tau pathology. While tau PET is clearly related to tauopathy by tracing brain neurofibrillary tangles, for p-tau it is less clear whether it reflects or rather anticipates early tangle formation. Several studies could show that the increase of fluid-based tau phosphorylated at threonine 181 (p181tau) and tau phosphorylated at threonine 217 (p217tau) is an early event of AD pathogenesis driven by β-amyloid deposition in brain [1, 3]. The tight link between β-amyloid deposition and CSF p-tau is also consistent with recent clinical data using anti-Aβ antibody Donanemab; concomitant with a reduction in Aβ plaques, plasma p217tau decreased while tauopathy still progressed, although at a slower rate [8]. However, whether β-amyloidosis per se, i.e. in the absence of neurofibrillary tangles and neuronal death, is sufficient to raise p-tau levels in the CSF is not clear [3]. We quantified endogenous p181tau in CSF samples of APPPS1 transgenic (tg) mice (see also Supplementary Methods, online resource) that do not develop neurofibrillary tangles or extensive neuron loss [9]. CSF p181tau in APPPS1 tg mice showed an age-dependent increase reaching a plateau at threeto four-fold higher levels in aged compared to 1.5-month-old mice (Fig. 1a). In non-tg littermates, CSF p181tau exhibited a biphasic profile with a transient drop reminiscent of CSF total tau (t-tau) levels in non-tg mice [10]. Total tau (t-tau) measured in the same CSF samples also plateaued in aged APPPS1 tg mice (Supplementary Fig. 1, online resource). The p181tau/t-tau ratio initially dropped but overall remained stable at 7–8% (Fig. 1b). CSF p181tau strongly correlated with CSF t-tau levels (Fig. 1c). We then used an immunoassay which allows the quantification of tau phosphorylated at threonine 217 with or without adjacent phospho-epitopes (“p217 + tau” [12] (see also Supplementary Methods, online resource). P217 + tau also showed an age-dependent increase and reached a plateau, although at 14to 16-fold higher levels compared to 1.5-month-old APPPS1 tg animals (Fig. 2a). The p217 + tau/ t-tau ratio was unchanged up to 6 months of age but started to increase thereafter (from 5 to 14%) becoming significant at 18 months of age (Fig. 2b). A strong correlation was observed between CSF p217 + tau and t-tau levels (Fig. 2c). Thus, overall changes in CSF p181tau, p217 + tau and t-tau tightly follow the Aβ deposition reported in this mouse model starting at 1.5 months with a plateau around 18 months of age [9, 10, 13]. The magnitude of the CSF p-tau increase is comparable to the p-tau increase observed in AD patients [7]. In AD, soluble p-tau also reaches its highest level in the phase of maximal cerebral amyloid load, but seems to decrease thereafter, presumably due to the occurrence of neuron loss during disease progression [1]. To test whether the increase of CSF p-tau is specific to the aggregation of Aβ or rather a shared consequence of different types of cerebral amyloidosis, we then assessed tau in the CSF of ADanPP tg mice, a model of Danish amyloidosis as seen in Familial Danish Dementia * Stephan A. Kaeser stephan.kaeser@uni-tuebingen.de

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-021-02400-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Kaeser, S. A., Häsler, L. M., Lambert, M., Bergmann, C., Bottelbergs, A., Theunis, C., Mercken, M., & Jucker, M.
Venue
Acta Neuropathologica
Published
2021-12-28
Volume
143
Issue
2
Pages
287-290
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W4200548419
Cited by
41
References
7
FWCI
4.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.